Inclusion Criteria:

- All patients must have a documented pathologic diagnosis of epithelial ovarian (FIGO
Stage I-IV), Fallopian tube or primary peritoneal carcinoma

- Patients must have received platinum-based, first-line chemotherapy but no more than
one additional prior chemotherapy regimen. Patients must have recovered from the
acute side effects of prior chemotherapy prior to enrollment in this trial.

- Patients must be considered to have platinum resistant disease based on the most
recent platinum-based regimen given, i.e., have had a treatment-free interval in
response to platinum of less than six months, or have progressed during
platinum-based therapy

- Presence of measurable disease or CA-125 > or = to 100 on two separate occasions at
least one week apart is required for this study

- Patient must have a Zubrod Performance Status of 0, 1 or 2

Exclusion

- Patients with a current diagnosis of epithelial ovarian tumor of low malignant
potential (borderline carcinomas) are not eligible. Patients with a prior diagnosis
of a low malignant potential tumor that was surgically resected and who have
subsequently developed invasive adenocarcinoma are eligible.

- Patients who are currently undergoing abdominal or pelvic radiation therapy or
patients who have received prior abdominal or pelvic radiation therapy are excluded.

- Patients with unstable angina or who have had a heart attack within the past six
months are not eligible to participate.

- Patients who have received prior Gemzar or Doxil therapy are ineligible.